Liquidia Slides Another 15% as Court Orders Remedy Plan in YUTREPIA Patent Loss
LQDA sits 23% above its 52-week low of $21.35 on elevated volume (7.6× avg).
Summary
Liquidia shares fell another 14.6% to $25.83 on Thursday, extending Wednesday's 25% plunge after a Delaware court ruled United Therapeutics' '327 patent claims valid and infringed by YUTREPIA. The court has ordered both parties to submit a proposed final judgment within one week, and United Therapeutics is seeking an order directing the FDA to withdraw YUTREPIA's approval. Liquidia's CEO said the company will appeal and plans to file a supplement to remove PH-ILD from the label, but the remedy could range from label changes to broader market restrictions. This follows the 8-K filed September 30 disclosing the adverse ruling. The key near-term event is the proposed judgment due within a week, which will clarify whether YUTREPIA faces removal from the U.S. market.
At the time of this announcement, LQDA was trading at $26.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $21.35 to $93.61. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.